Shanghai Yuesai Biotechnology

Shanghai Yuesai Biotechnology (UniXell Biotechnology) is a clinical-stage biopharmaceutical company founded in 2021, specializing in the development of next-generation cell therapies derived from human induced pluripotent stem cells (iPSCs). The company leverages its proprietary platforms for stem cell reprogramming, differentiation, and high-precision gene editing, including the SISBAR lineage tracing technology, to create high-purity neural cell products. Its lead candidate, UX-DA001, is an autologous iPSC-derived dopaminergic neural precursor therapy for Parkinson's disease currently in Phase 1 trials. Additionally, the company is advancing UX-GIP001, an allogeneic therapy for focal epilepsy that has received IND clearance from both the FDA and NMPA. Headquartered in Shanghai, UniXell operates a 4,000-square-meter R&D and GMP manufacturing facility and is supported by a strong consortium of venture capital investors.